 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is our internal ID - starting with VT.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
- For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.
 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients with Malignant Glioma |
 |
 |
 |
 |
 |
 |
Keywords: |
 |
ANG1005, paclitaxel |
 |
 |
 |
 |
Phase: |
 |
Phase 1 |
 |
 |
 |
 |
 |
 |
Treatment ID#s: |
 |
VT1862
2007-0931
|
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
Not Specified |
 |
 |
 |
 |
Conditions: |
 |
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma (WHO Grades II, II, or IV) with evidence of tumor progression |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
05/28/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
ANG1005 is a conjugate consisting of paclitaxel and Angiopep2. Angiopep2 is a peptide designed to help drugs cross the brain blood barrier. When ANG1005 is transported across the brain blood barrier and reaches the cancer cells, it is internalized to release paclitaxel. ANG1005 has been shown to inhibit tumor cell proliferation, block tumor cell cycle progression and induce b-tubulin polymerization.
|
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy. |
 |
 |
 |
 |
Contact: |
 |
MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/ |
 |
 |
|
|